Earnings Labs

Viatris Inc. (VTRS)

Q3 2023 Earnings Call· Tue, Nov 7, 2023

$14.76

-0.27%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.

Same-Day

+0.99%

1 Week

+2.52%

1 Month

+10.95%

vs S&P

+5.63%

Transcript

Operator

Operator

Hello. My name is Travis, and I will be your conference operator today. At this time, I would like to welcome everyone to the Viatris 2023 Third Quarter Earnings Call and Webcast. All participant lines have been placed on mute to prevent any background noise. After the speakers remarks there’ll be a question and answer period. [Operator Instructions]. I will now turn the call over to Bill Szablewski, Head of Global Capital Markets. Please go ahead, sir.

William Szablewski

Analyst

Good evening, everyone. Welcome to our third quarter 2023 earnings call. With us today is our CEO, Scott Smith; President, Rajiv Malik; and CFO, Sanjeev Narula. During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2023 and various strategic initiatives. These statements are subject to risks and uncertainties that could cause future results or events to differ materially from today's projections. Please refer to today's slide presentation and our SEC filings for a fuller explanation of those risks and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures to supplement investors' understanding and assessment of our financial performance. Reconciliations of those non-GAAP measures to the most directly comparable GAAP measures, are available on our website and in the appendix of today's [Technical difficulty]. discussion, we will be making certain comparisons of results on an operational basis, which excludes the impact of foreign currency rates versus the plan that supports our [Technical difficulty] prior period results, which also exclude the results from the divested bio-similar business. An archived copy of today's presentation and other earnings materials will be available on our website at investor.viatris.com following the conclusion of today's call. With that, I'll hand the call over to our CEO, Scott Smith.

Scott Smith

Analyst

Good afternoon. I'm pleased to report that Viatris had another outstanding quarter in Q3. We achieved our second consecutive quarter of year-over-year operational revenue [Technical difficulty] our 11th [Technical difficulty] operating results and consistently [Technical difficulty] metrics. All evidence that we continue to build momentum as we bring the Phase 1 of our strategic plan to successful completion. In the third quarter, we delivered total revenues of $3.94 billion, representing approximately 1% year-over-year growth. And adjusted EBITDA of $1.36 billion and free cash flow of $738 million, both of which, as you will hear more about from Sanjeev later were above our expectations. Based on our strong operational performance in the first 9 months of the year, we are reaffirming our 2023 financial guidance ranges for adjusted EBITDA and free cash flow. Company is delivering strong operational revenues in line with our expectations. However, the impact of foreign exchange headwinds requires that we make a modest adjustment to our 2023 total revenue guidance range due solely to these FX headwinds. In addition, at the end of the third quarter, we were pleased to announce that we entered into agreements on all our planned divestitures. Announcing these transactions marked the achievement of an important milestone in the execution of our Phase 1, strategic plan. We ran a strong and competitive process, and we're able to sign agreements to divest substantially all of our over-the-counter business, our women's health care business, our API business in India, and commercialization rights in certain noncore markets that were acquired as part of the Upjohn transaction. All within our previously announced time lines and valuation ranges. We anticipate closing all these transactions by the end of the first half of 2024. As we look to 2024 and beyond, the momentum we see in the business gives…

Rajiv Malik

Analyst

Thanks Scott. I appreciate it and look forward to working with you to ensure a smooth transition while continuing to support you as we look out into the future, but in a different capacity. I also want to take the opportunity to thank all of our employees who have helped us build this strong global platform. I'm very pleased with where we are today in Viatris journey and the strength as well as stability of our core business, which is now nicely set up for the continued growth from here onwards. Moving to our Commercial segment results. We have delivered a second consecutive quarter of year-over-year operational top line growth as we predicted, which further reaffirms that we are standing strong and set up for the future. This quarter, we recorded 1% year-over-year operational growth and are well positioned to end the full year in line with our expectations. Our well-balanced business of developed markets delivered another strong quarter growing 2% year-over-year operationally. Europe grew 1% versus the prior year on an operational basis, making it the seventh consecutive quarter of year-over-year growth. France and Italy led the growth in the region. A solid performance of generics in the Europe was another contributing factor. Our North America business was up 4% year-over-year on an operational basis, in line with our expectations. Our generics portfolio performed better than expected, driven by new launches such as Breyna, the generic for Symbicort, Lisdexamfetamine and the continued contribution of lenalidomide. Also some other key products, including glatiramer acetate, vancomycin and Xulane performed better than expectations. Our brand business was supported by strong demand in YUPELRI, which grew 9% this quarter over the last year and in the epinephrine market. Overall, we remain confident that the developed market segment will meet our full year expectations.…

Sanjeev Narula

Analyst

Thank you, and hello, everyone. Before I begin, I would also like to extend my congratulations to Rajiv. It has been a great partnership over the past 3 years, and I am proud of what we've accomplished together. We trust our colleagues and patients all over the world to benefit from your leadership, expertise and dedication to our business. Turning to our outlook. I want to reiterate my confidence in the strength of our unique global platform in the continued durability of our significant free cash flow generation. We're pleased with the outcome of our announced divestiture. Which upon closing will bring the successful conclusion to our Phase 1 commitments and further serves to accelerate our financial flexibility. As we work to finalize the plan for next year, and although we are not providing guidance at this time, we continue to expect at least $2.3 billion in free cash flow in 2024 even when taking into consideration inflation and foreign exchange headwinds to date. This excludes any taxes and transaction costs associated with divestiture. For the second consecutive quarter, the business delivered total operational revenue growth versus prior year. The performance was diversified across regions and categories. The positive mix of brand and new products drove strong gross margins. From a regional perspective, we saw 2% growth in net sales from developed and emerging markets. The growth included the benefit from brands, generics and new launches. Net sales for the quarter were in line with the expectation and grew 1% versus the prior year. A diverse portfolio of growth driver included brand performance in emerging markets, Europe and Greater China. These revenue trends and positive momentum are expected to continue as we exit the year driven by brand strength of our global generic portfolio and new products. New product revenue…

Operator

Operator

[Operator Instructions] Our first question comes from Chris Schott, JPMorgan.

Christopher Schott

Analyst

Great. Here was on how envisioning kind of capital deployment and specific [Technical difficulty] the divestiture verticals that you talked about in the past I'm trying to get my hands around. Is this something that we -- you're kind of actively looking at this point? Or we need to wait for the transactions to close and the sense of being more kind of 2025 and beyond kind of event that we think about kind of the redeployment of some of the cash coming in the door? Or just any color you can provide there would be much appreciated? Thanks so much.

Scott Smith

Analyst

Thank you, Chris. Thank you very much for the question. Yes, we're looking for innovative high-growth assets that bring in predictable, durable revenue streams, good fit for our business that we can leverage strong global infrastructure we have. You asked about the verticals, we're definitely looking at things in the verticals. We're also going to be a little bit agnostic. And if there's a good opportunity that lies outside of those verticals we will look at that very, very closely as well. The important thing for me is whatever we do, we want to leverage the global strength that we have as a company. And in terms of business development, I look at it in sort of in 3 buckets. M&A, of course, but also licensing is very, very important and partnership is very, very important. Some of them are more capital-intensive than others. And in terms of speculating on timing, I don't think -- again, I won't speculate on timing at this point. I think we're looking at things very actively right now, and we'll see where we get. But we're excited about the opportunities that are out there. I think there's a lot of opportunities where we're going and what we're doing. So I appreciate the question.

Operator

Operator

Our next question comes from Nathan Rich, Sachs.

Nathan Rich

Analyst

Great. Good afternoon, and thanks for the question. I wanted to ask on the kind of transition to Phase II. And you gave some details around the 2022 EBITDA of the announced divestitures. Now I know you don't want to give EBITDA guidance for 2024. But any color you can provide on how those businesses have trended over the past year? And any other considerations from a cost standpoint that we should think about? And then as we think about the transformation of the business and the acceleration of top line growth, can you maybe think about help us walk through what the building blocks are to eventually getting the business to that kind of 3% revenue CAGR that you're targeting in Phase II?

Scott Smith

Analyst

Yes. So first of all, yes, to '24, I feel great about where we're going in '24. We've had now 2 consecutive quarters of operational growth, and we believe we'll finish '23 strong. I think it will set us up very, very nicely for '24. We have full confidence that we're on track to meet our previously stated long-term goals. I guess really importantly, we expect to have at least $2.3 billion in free cash flow in '24 and beyond. Even when you take into consider inflation, FX headwinds, et cetera. I think there's a very, very strong base to the business, and we expect to grow just with the base business, as you mentioned, in that 3% range. Just off to base the business that we have a very stable, growing, strong globally right now. But we hope to even have a significantly higher growth rate than that from a revenue perspective as we start to invest in business development and other businesses and bring other assets in that can complement the organization that we have in place. And Rajiv, I think there was a question around divestiture.

Rajiv Malik

Analyst

Yes. No, that was a specific question, Dave, can you speak on divestiture?

Nathan Rich

Analyst

If we tell them 2022, how those businesses were trending, divestiture.

David Bayles

Analyst

First of all, from the overall business point of view as well as between 2 divestitures, all our businesses are performing as we anticipated or better than we had anticipated, including whether it's geography or whether it's the brands, generics and those categories. And that holds basically true for also the businesses which we have identified and which are going through the divestiture. But also, Scott, to your point, the 3%, which we have growth, which we have indicated, just to add on to that, that included our base business, what we have in pipeline for today, that didn't include any more deployment of the capital deployment, which may come from '24 onwards, that will be on top of that. So I just wanted to also build upon that.

Sanjeev Narula

Analyst

And one other thing to keep in mind, the business is that we're divesting. Their margins are generally less than the company average. So what we expect post divestment, company's margin like gross margin to be stable. From that perspective. That's an important thing to keep in mind as well.

Scott Smith

Analyst

I also want to piggyback off what Rajiv said. And as we start to really pivot to real growth from a revenue perspective and given our capital allocation plan and our desire to buy back shares. We can move the story to a long-term adjusted EPS growth story, which we're very excited to move into that early part.

Operator

Operator

Our next question comes from Umer Raffat, Evercore.

Umer Raffat

Analyst

Hi, guys. Thanks for taking my question. I wanted to focus on China business for a second. And it looks like your China business is holding in broadly fairly stable, except for FX. And it appears to be quite different in performance versus what some of your peer companies also with meaningful China businesses have reported. And I kind of see that not just on the emerging markets sales reported -- sorry, Greater China sales reported but also in the product level breakout. So I'm just curious, what do you think is tracking different and or is there some timing of revenue recognition that is playing out and maybe we do see some weakness in 4Q? Because it does seem like it's a little more industry-wide? Thank you.

Scott Smith

Analyst

Umer, I can't speak about our peers, I can speak about our China business, which right from ever since we have gone through this evolution around the policy dynamics and all that live through our 95% business has gone through the VBP. We had gone through the cycles of VBP. And we have taken this time to reorient and shift our business more towards a private paid channel. And that's what we have seen. We have found that the equilibrium between the hospital and private pay channel, and we have been trying to invest more on that. And investing in the pipeline, for example, even this quarter, just getting the Yupelri positive data because Yupelri and Dymista performance now going through the approval channels and also the pipeline. We cannot be more excited about what we are seeing in the underlying business or the fundamentals of our China business. Extending that to emerging markets. We take our time to figure out how to manage this the hybrid business we have between the brand as well as the generics, and we have found that sweet spot and you see emerging markets business, the brand is performing better than expected, generic performing better than expected. So I can speak about our business, we seem very confident and optimistic about this business, and that's what is entering the stability to the base. And coupled with the new launches, new launch revenue, I think that's what is driving based growth of 1% year-over-year, 1% which you see in that.

Operator

Operator

Our next question comes from Glen Santangelo, Jefferies.

Glenn Santangelo

Analyst

Thanks for taking my question. I just wanted to follow up, Rajiv, on some of the comments you were just talking about that the generics business was performing better than expected. Could you maybe talk about the pricing environment in terms of what you saw in the quarter? And if there's any discernible trends that are worth sort of calling out? And any sort of comments around the sustainability of that recent trend would be helpful. Thanks.

Rajiv Malik

Analyst

Glen, after several quarters, I can say that we have seen -- I'm not -- we have seen perhaps a longer stretch of stability after so many years, I would say. And I don't see any trend at the moment because it's a generic business that plan. It's both demand and supply. And at this point of time, is that we see some still supply disruptions going on, on some key molecules and key products. And it's about your own portfolio, your own ability to supply and basically the flexibility in the supply to sometimes respond to the market needs. And that's what I think we have set for ourselves, and that's got giving us a stability. And I don't see at the moment in the environment, some more trends which we should be concerned about.

Operator

Operator

Our next question comes from Jason Gerberry, Bank of America.

Jason Gerberry

Analyst

Thanks for taking my question. Just wanted to inquire about the inflationary pressures on cost of goods that was flagged last quarter. It appears like either that was maybe not realized this quarter because of mix or perhaps there were some other offsets. Really curious more so just to think about how those inflationary pressures, do you feel like you may see those manifest in 4Q or into next year? That would be helpful. Just some of your peers have flagged inflationary pressures as well in cost of goods. So just wondering if you can level set? Thanks.

Sanjeev Narula

Analyst

Yes. So Jason, thank you for the question. So we had anticipated inflation pressure, and we've kind of talked about that when we made our plan give the guidance to that. We're managing our costs very well. So the impact is still there for inflation. And in this quarter, we have an inflation impact, but it is less than what we had anticipated. So clearly, our teams are doing a great job in managing the cost. And you can see that reflected in our gross margin, which is coming better than we expected. And we've actually raised the full year metrics to 58.75% on the strength of mix and us managing the cost, including inflation, better than what we had anticipated.

Operator

Operator

Our next question comes from Ash Verma, UBS.

Ash Verma

Analyst

Thanks for taking my question. So on emerging markets, can you elaborate the dynamic here a little bit? You mentioned customer buying patterns impacting 3Q? I didn't hear you saying that you're going to expect to get to the outlook that you had for the emerging market, although I heard that for other geographies? And second one, I just wanted to understand the FX impact. So 3Q revenue saw a $7 million headwind, but you're lowering your 2023, midpoint by $250 million. Is this all concentrated in just 4Q alone? Thanks.

Rajiv Malik

Analyst

I think on emerging market, some of our key brands, Lyrica, Zoloft, Effexor region, some of the brands have been performing pretty well. Turkey -- and also emerging Asia, we call it, this is geographies like Thailand and [indiscernible] and all those countries put together. They have performed above expectations. And I see this trend continue. I mean I see emerging markets well under track for mid-single-digit growth, year-over-year growth, driven on the strength of their portfolio, diversity and markets where we are seeing that confidence. Sanjeev?

Sanjeev Narula

Analyst

Yes. Yes. So Ash, on the FX, a couple of comments. So what's going on in the three currencies? So 70% of our business is non-U.S. dollar denominated. 50% comes from three currencies, which is the euro, Japanese yen and Chinese RMB. What was going on until about September as you could probably track that. Dollar had sense against the Chinese RMB and Japanese yen. And then euro was favorable to what we had assumed. But September onwards, the euro started weakening with all the Fed action that was going on. So whatever the offset that we were seeing in the first half of the year went away. So you see the impact is much bigger now starting September in fourth quarter than we had anticipated, and that's what we are reflecting in our full year guidance, assuming the October 8 stands. So it's all three currencies. It's all FX and operationally exactly in line with what we had anticipated. And you saw that we reaffirmed our guidance on EBITDA and free cash flow absorbing the FX impact.

Operator

Operator

Our next question comes from Balaji Prasad, Barclays.

Unidentified Analyst

Analyst

Macula [ph] on for Balaji. Thanks for taking our questions. Just wondering if you guys have any thoughts on today's move by the FTC to challenge more than 100 in popular patents listed in the FDA's Orange Book. I'm wondering if this will have any impact to the interest. Thanks.

Brian Roman

Analyst

So this is Brian Roman, the General Counsel. Thanks for the question. Our company has been an industry leader in challenging and proper Orange Book listings for many years. So this is an issue that we understand well, take seriously, and frankly, I'd like to see the issue getting some attention. That QC hasn't shared with us what concern they have about these particular patents. But I'd add that there already has been for years’ significant generic competition for our epinephrine auto-injectors.

Operator

Operator

Our next question comes from David Amsellem, Piper Sandler.

David Amsellem

Analyst

So just a couple of product-specific questions. Can you talk about how you're thinking about the generic Symbicort contribution next year? I know you talked about revenue being a below expectations and developed markets because of phasing of that product. So just talk about where that product is heading. Then any update on iron sucrose that would be helpful. And then on business [Technical difficulty]. What's your willingness to move away from that or look at other therapeutic silos? Thanks.

Rajiv Malik

Analyst

So I'll answer the sort of the last part of the question first. And as I said earlier, that those three verticals, we think very highly of in terms of the type of assets that are there [Technical difficulty] areas, but we'll keep our minds open. [Technical difficulty] All right there that can help us really move the company away. Again, what we're really looking to do leverage the company. And if there are assets outside of those 3 areas that we find that can really help us secure our growth in Phase II, we'll definitely look at them.

Sanjeev Narula

Analyst

And David on launch of Breyna generic with the Symbicort. We couldn't be more pleased to launch another complex part to make products as affordable alternative to [Technical difficulty] we are looking at the pickup of market share. Now isn't kept for customers, for example, we can be in some comment -- selling to some common entities, veterans or issues like [indiscernible]. So it doesn't capture -- we are -- it's exactly how we are model. It's going to be a significant contributor because we don't see a competition on horizon at this point of time for the next year, it's going to be a meaningful contributor to that. And the miss -- and I won't call -- first of all, we are very happy to have more than $450 million. We have already captured $345 million on new launches, and we are well on track to do more than $450. [Technical difficulty] Most likely the launch being early the first quarter early in the first quarter of the next year. And nothing has changed otherwise, we are exactly on track. We delivered exactly how we planned.

A - Scott Smith

Analyst

Are there any more questions in line?

Operator

Operator

No sir. I would now like to turn the call back over to Scott Smith, CEO, to make a few closing remarks.

Scott Smith

Analyst

Thank you very much, and thank you to everybody on the call. In summary, I'm very, very pleased with the overall execution momentum and the momentum that we have as we bring Phase 1 of our strategic plan to a successful conclusion. I'm very much looking forward to moving into Phase II of our strategic plan, and I fully believe in the future trajectory of Viatris, and I'm very excited for what's to come. Thank you all again for your attention.

Operator

Operator

This does conclude today's Viatris 2023 third quarter earnings call and webcast. Please disconnect your line at this time, and have a wonderful day.